Purpose This study aimed to evaluate the cost-effectiveness of dabigatran and rivaroxaban
compared with warfarin for the prevention of stroke in patients with atrial fibrillation (AF) in …

Background and objective To evaluate the cost-effectiveness of new anticoagulants and
warfarin in the prevention of stroke in Chinese patients with atrial fibrillation (AF). Methods …

Background and Purpose—To estimate the cost-effectiveness of stroke prevention in
patients with nonvalvular atrial fibrillation by using novel oral anticoagulants apixaban 5 mg …

Abstract Purpose In China, dabigatran and rivaroxaban are the only approved non–vitamin
K antagonist oral anticoagulants for the treatment of atrial fibrillation (AF). The goal of this …

Background No studies have directly compared the effectiveness and safety of dabigatran
and rivaroxaban using US Medicare data. Objective Our objective was to compare …

Canadian patients with atrial fibrillation (AF) in whom anticoagulation is appropriate have
two new choices for anticoagulation for prevention of stroke and systemic embolism …

Background To compare the management cost and cost‐effectiveness of dabigatran with
warfarin in patients with nonvalvular atrial fibrillation (AF) from the hospital's and patients' …

ABSTRACT Background and Objectives: Rivaroxaban is noninferior to warfarin for
preventing stroke or systemic embolism in patients with high-risk atrial fibrillation (AF) and is …

Objectives Our objectives were to investigate the cost effectiveness of apixaban,
rivaroxaban, and dabigatran compared with coumarin derivatives for stroke prevention in …

Objectives The primary objective was to assess the cost-effectiveness of new oral
anticoagulants compared with warfarin in patients with nonvalvular atrial fibrillation …